The study evaluated the hepatitis B virus (HBV) status of children born to women who were coinfected with HIV and HBV, focusing on those who had access to antiretroviral therapy from 2000 to 2012.
Out of 35 children studied, 74% developed protective antibodies against HBV after receiving HBV immunoglobulin and vaccines, indicating that maternal treatment with lamivudine or tenofovir/emtricitabine during pregnancy was effective.
No child showed signs of chronic HBV infection, but there were instances of incomplete vaccination and uncertainty about immunoglobulin receipt, underscoring the need for larger studies to assess long-term vaccine protection.
The study investigates Hepatitis B Virus (HBV) Mother-To-Child Transmission (MTCT) among HIV/HBV co-infected women, which has been less studied compared to HIV MTCT.
Out of 530 HIV-infected women, 49 were co-infected, with 34 giving birth to 57 children during the study period; follow-up data were available for 21 women and their 35 children.
Results showed that 74.3% of the children had protective HBV antibodies, with a significant correlation between receiving immunoglobulin at birth, complete vaccination, and positive outcomes against HBV.